Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for ABUS

Stock NameArbutus Biopharma Corp
TickerABUS(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINCA03879J1003

Show aggregate ABUS holdings

News associated with ABUS

Wall Street Zen Downgrades Arbutus Biopharma (NASDAQ:ABUS) to Hold
Wall Street Zen cut shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a buy rating to a hold rating in a research note issued to investors on Friday morning. Separately, Chardan Capital reaffirmed a “buy” rating and set a $5.00 target price on shares of Arbutus Biopharma in a report on Monday, August 11th. […] - 2025-09-08 02:54:58
Arbutus Biopharma Corp. Q2 Earnings Summary
(RTTNews) - Below are the earnings highlights for Arbutus Biopharma Corp. (ABUS): - 2025-08-06 08:49:24
10,000 Shares in Arbutus Biopharma Corporation (NASDAQ:ABUS) Bought by Cyndeo Wealth Partners LLC
Cyndeo Wealth Partners LLC bought a new position in Arbutus Biopharma Corporation (NASDAQ:ABUS – Free Report) in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $35,000. Other hedge funds and other institutional investors have also […] - 2025-06-18 05:50:55
Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Acquired by Wellington Management Group LLP
Wellington Management Group LLP grew its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 3.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 513,302 shares of the biopharmaceutical company’s stock after acquiring an additional 16,484 shares during the period. Wellington Management Group LLP’s holdings in Arbutus Biopharma were worth $1,678,000 […] - 2025-06-06 05:38:53
Millennium Management LLC Grows Stock Position in Arbutus Biopharma Co. (NASDAQ:ABUS)
Millennium Management LLC boosted its position in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 36.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 343,028 shares of the biopharmaceutical company’s stock after buying an additional 92,068 shares during the quarter. Millennium Management LLC’s […] - 2025-06-05 04:24:59
ProShare Advisors LLC Grows Position in Arbutus Biopharma Co. (NASDAQ:ABUS)
ProShare Advisors LLC increased its position in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 29.3% in the fourth quarter, HoldingsChannel reports. The firm owned 50,121 shares of the biopharmaceutical company’s stock after purchasing an additional 11,359 shares during the quarter. ProShare Advisors LLC’s holdings in Arbutus Biopharma were worth $164,000 as of its most […] - 2025-06-02 05:03:00
Deutsche Bank AG Increases Stake in Arbutus Biopharma Co. (NASDAQ:ABUS)
Deutsche Bank AG increased its stake in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 77.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 171,766 shares of the biopharmaceutical company’s stock after acquiring an additional 75,212 shares during the quarter. Deutsche Bank AG’s holdings in Arbutus Biopharma were worth $562,000 at the end of […] - 2025-05-29 04:44:55
Northern Trust Corp Has $4.35 Million Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)
Northern Trust Corp increased its stake in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 8.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,330,683 shares of the biopharmaceutical company’s stock after acquiring an additional 102,241 shares during the period. Northern Trust Corp’s holdings in Arbutus Biopharma were worth $4,351,000 at the end of […] - 2025-05-22 04:22:55
Invesco Ltd. Purchases 3,780 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)
Invesco Ltd. grew its position in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 5.7% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 69,831 shares of the biopharmaceutical company’s stock after buying an additional 3,780 shares during the period. Invesco Ltd.’s holdings in Arbutus Biopharma […] - 2025-05-05 04:26:47
XTX Topco Ltd Acquires 22,568 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)
XTX Topco Ltd raised its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 75.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 52,581 shares of the biopharmaceutical company’s stock after purchasing an additional 22,568 shares during the quarter. XTX Topco Ltd’s holdings in Arbutus Biopharma were worth $172,000 at the […] - 2025-04-29 05:24:53
Rockefeller Capital Management L.P. Has $349,000 Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)
Rockefeller Capital Management L.P. boosted its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 69.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 106,615 shares of the biopharmaceutical company’s stock after acquiring an additional 43,615 […] - 2025-04-24 06:00:57
Arbutus Biopharma Announces Acceptance of Five Abstracts for Presentation at EASL Congress 2025
Arbutus Biopharma announces five abstracts accepted for EASL Congress 2025, focusing on hepatitis B therapies and clinical trials. - 2025-04-23 03:10:26
Bank of Montreal Can Purchases 15,567 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)
Bank of Montreal Can grew its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 3.5% in the 4th quarter, HoldingsChannel.com reports. The fund owned 455,880 shares of the biopharmaceutical company’s stock after purchasing an additional 15,567 shares during the quarter. Bank of Montreal Can’s holdings in Arbutus Biopharma were worth $1,491,000 as of […] - 2025-04-18 05:06:53
25,600 Shares in Arbutus Biopharma Co. (NASDAQ:ABUS) Acquired by KLP Kapitalforvaltning AS
KLP Kapitalforvaltning AS acquired a new stake in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 25,600 shares of the biopharmaceutical company’s stock, valued at approximately $84,000. A number of […] - 2025-04-11 04:49:00
Mitsubishi UFJ Asset Management Co. Ltd. Decreases Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS)
Mitsubishi UFJ Asset Management Co. Ltd. lessened its holdings in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 15.0% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 69,660 shares of the biopharmaceutical company’s stock after selling 12,287 shares during the period. […] - 2025-04-04 05:12:59
Intech Investment Management LLC Has $187,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS)
Intech Investment Management LLC increased its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 54.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 57,084 shares of the biopharmaceutical company’s stock after buying an additional 20,232 shares during the quarter. […] - 2025-03-28 07:12:50
Cibc World Markets Corp Takes $45,000 Position in Arbutus Biopharma Co. (NASDAQ:ABUS)
Cibc World Markets Corp bought a new position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 13,672 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Other institutional investors and hedge funds […] - 2025-03-28 06:18:44
Arbutus Biopharma Co. (NASDAQ:ABUS) Sees Large Growth in Short Interest
Arbutus Biopharma Co. (NASDAQ:ABUS – Get Free Report) was the target of a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 8,410,000 shares, a growth of 16.6% from the February 13th total of 7,210,000 shares. Approximately 4.6% of the shares of the stock are […] - 2025-03-21 04:26:50
Arbutus Biopharma (NASDAQ:ABUS) Downgraded to “Sell” Rating by StockNews.com
StockNews.com cut shares of Arbutus Biopharma (NASDAQ:ABUS – Free Report) from a hold rating to a sell rating in a research report released on Thursday morning. A number of other equities research analysts also recently commented on ABUS. Chardan Capital reissued a “buy” rating and issued a $5.00 price objective (up from $4.50) on shares […] - 2025-03-14 06:26:49
Comparing Arbutus Biopharma (NASDAQ:ABUS) & Akari Therapeutics (NASDAQ:AKTX)
Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) and Akari Therapeutics (NASDAQ:AKTX – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership. Risk and Volatility Arbutus Biopharma has a […] - 2025-03-12 04:56:53
Arbutus Biopharma (NASDAQ:ABUS) Upgraded by StockNews.com to “Hold” Rating
Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Wednesday. Other equities analysts have also issued reports about the company. JMP Securities boosted their price target on Arbutus Biopharma to $5.00 and gave the company a […] - 2025-03-07 04:10:47
Arbutus Biopharma (NASDAQ:ABUS) Cut to “Sell” at StockNews.com
Arbutus Biopharma (NASDAQ:ABUS – Get Free Report) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Tuesday. Other equities research analysts have also issued reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $5.00 price objective on shares of […] - 2025-02-27 04:15:04
China Universal Asset Management Co. Ltd. Buys 3,870 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)
China Universal Asset Management Co. Ltd. grew its stake in Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 10.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 40,179 shares of the biopharmaceutical company’s stock after acquiring an additional 3,870 […] - 2025-02-04 06:53:07

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc ABUS holdings

DateNumber of ABUS Shares HeldBase Market Value of ABUS SharesLocal Market Value of ABUS SharesChange in ABUS Shares HeldChange in ABUS Base ValueCurrent Price per ABUS Share HeldPrevious Price per ABUS Share Held
2025-11-12 (Wednesday)125,560ABUS holding increased by 23274USD 607,710ABUS holding increased by 125943USD 607,71023,274USD 125,943 USD 4.84 USD 4.71
2025-11-11 (Tuesday)102,286USD 481,767ABUS holding increased by 12274USD 481,7670USD 12,274 USD 4.71 USD 4.59
2025-11-10 (Monday)102,286USD 469,493ABUS holding increased by 9206USD 469,4930USD 9,206 USD 4.59 USD 4.5
2025-11-07 (Friday)102,286USD 460,287ABUS holding increased by 6137USD 460,2870USD 6,137 USD 4.5 USD 4.44
2025-11-06 (Thursday)102,286ABUS holding decreased by -335USD 454,150ABUS holding decreased by -18933USD 454,150-335USD -18,933 USD 4.44 USD 4.61
2025-11-05 (Wednesday)102,621ABUS holding decreased by -3350USD 473,083ABUS holding decreased by -3787USD 473,083-3,350USD -3,787 USD 4.61 USD 4.5
2025-11-04 (Tuesday)105,971ABUS holding decreased by -670USD 476,870ABUS holding decreased by -11546USD 476,870-670USD -11,546 USD 4.5 USD 4.58
2025-11-03 (Monday)106,641ABUS holding decreased by -670USD 488,416ABUS holding decreased by -19165USD 488,416-670USD -19,165 USD 4.58 USD 4.73
2025-10-31 (Friday)107,311USD 507,581ABUS holding decreased by -11804USD 507,5810USD -11,804 USD 4.73 USD 4.84
2025-10-30 (Thursday)107,311USD 519,385ABUS holding increased by 24681USD 519,3850USD 24,681 USD 4.84 USD 4.61
2025-10-29 (Wednesday)107,311USD 494,704ABUS holding increased by 3220USD 494,7040USD 3,220 USD 4.61 USD 4.58
2025-10-28 (Tuesday)107,311ABUS holding increased by 1005USD 491,484ABUS holding increased by 16296USD 491,4841,005USD 16,296 USD 4.58 USD 4.47
2025-10-27 (Monday)106,306USD 475,188ABUS holding increased by 11694USD 475,1880USD 11,694 USD 4.47 USD 4.36
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of ABUS by Blackrock for IE00B3VWM098

Show aggregate share trades of ABUS

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-11-12BUY23,2744.8704.630 4.654USD 108,317 3.52
2025-11-06SELL-3354.6004.350 4.375USD -1,466 3.50 Loss of -293 on sale
2025-11-05SELL-3,3504.6204.285 4.318USD -14,467 3.49 Loss of -2,764 on sale
2025-11-04SELL-6704.5784.450 4.463USD -2,990 3.49 Loss of -654 on sale
2025-11-03SELL-6704.7604.570 4.589USD -3,075 3.48 Loss of -742 on sale
2025-10-28BUY1,0054.5804.610 4.607USD 4,630 3.45
2025-10-24SELL-3354.3604.440 4.432USD -1,485 3.44 Loss of -333 on sale
2025-10-15BUY2,0104.4704.480 4.479USD 9,003 3.39
2025-10-02BUY3354.4904.600 4.589USD 1,537 3.38
2025-09-30BUY6704.5404.550 4.549USD 3,048 3.36
2025-08-21SELL-3353.5803.580 3.580USD -1,199 3.33 Loss of -83 on sale
2025-07-31BUY1,0023.2803.370 3.361USD 3,368 3.33
2025-06-30SELL-6703.0903.120 3.117USD -2,088 3.35 Profit of 158 on sale
2025-06-25SELL-3353.3403.400 3.394USD -1,137 3.36 Loss of -13 on sale
2025-06-20SELL-6703.4303.540 3.529USD -2,364 3.35 Loss of -117 on sale
2025-05-23BUY3353.2203.240 3.238USD 1,085 3.34
2025-05-19SELL-3353.1303.160 3.157USD -1,058 3.34 Profit of 62 on sale
2025-05-15SELL-1,0053.1203.150 3.147USD -3,163 3.35 Profit of 202 on sale
2025-05-12SELL-3353.3503.370 3.368USD -1,128 3.35 Loss of -5 on sale
2025-05-09SELL-3353.2303.370 3.356USD -1,124 3.35 Loss of -1 on sale
2025-04-30SELL-3353.5503.620 3.613USD -1,210 3.35 Loss of -90 on sale
2025-04-24SELL-6703.3403.350 3.349USD -2,244 3.35 Loss of -3 on sale
2025-04-17SELL-3353.1503.160 3.159USD -1,058 3.36 Profit of 66 on sale
2025-04-15SELL-1,0053.1603.340 3.322USD -3,339 3.36 Profit of 41 on sale
2025-04-14SELL-1,0053.2803.310 3.307USD -3,324 3.36 Profit of 58 on sale
2025-04-09SELL-1,3403.1703.230 3.224USD -4,320 3.37 Profit of 202 on sale
2025-04-07SELL-2,3453.0103.140 3.127USD -7,333 3.39 Profit of 613 on sale
2025-04-04SELL-3,3603.2303.460 3.437USD -11,548 3.39 Loss of -155 on sale
2025-03-31BUY3363.4903.540 3.535USD 1,188 3.39
2025-03-19SELL-6723.3103.320 3.319USD -2,230 3.39 Profit of 49 on sale
2025-03-17BUY29,9763.2803.310 3.307USD 99,131 3.40
2025-03-14SELL-1,4643.3003.410 3.399USD -4,976 3.40 Profit of 1 on sale
2025-03-13SELL-4903.3203.510 3.491USD -1,711 3.40 Loss of -44 on sale
2025-03-12SELL-8,3303.1903.200 3.199USD -26,648 3.41 Profit of 1,727 on sale
2025-03-07SELL-4903.3103.420 3.409USD -1,670 3.42 Profit of 7 on sale
2025-03-06SELL-7353.3703.550 3.532USD -2,596 3.42 Loss of -79 on sale
2025-03-04BUY34,8683.3903.570 3.552USD 123,851 3.42
2025-03-03SELL-1513.4203.520 3.510USD -530 3.42 Loss of -13 on sale
2025-02-28SELL-36,6423.4503.490 3.486USD -127,734 3.42 Loss of -2,264 on sale
2025-02-26SELL-2463.4403.560 3.548USD -873 3.43 Loss of -30 on sale
2025-02-25SELL-7383.4503.700 3.675USD -2,712 3.42 Loss of -185 on sale
2025-02-18BUY1,2303.3603.440 3.432USD 4,221 3.43
2025-02-13BUY2463.3003.360 3.354USD 825 3.45
2025-02-12BUY2463.3103.320 3.319USD 816 3.45
2025-02-11BUY7383.3103.340 3.337USD 2,463 3.46
2025-02-06BUY2,2053.4103.620 3.599USD 7,936 3.47
2025-01-27BUY2453.4303.450 3.448USD 845 3.53
2024-12-06BUY9803.6803.730 3.725USD 3,651 3.51
2024-12-05BUY2453.6303.790 3.774USD 925 3.49
2024-12-04BUY1,2253.7403.750 3.749USD 4,593 3.45
2024-11-29BUY1,2253.4603.510 3.505USD 4,294 3.45
2024-11-27BUY9803.4703.500 3.497USD 3,427 3.41
2024-11-26BUY2453.4103.470 3.464USD 849 0.00
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ABUS

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.